Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleBehavioral Pharmacology

Influence of Contingent and Noncontingent Drug Histories on the Development of High Levels of MDPV Self-Administration

Michelle R. Doyle, Agnieszka Sulima, Kenner C. Rice and Gregory T. Collins
Journal of Pharmacology and Experimental Therapeutics November 2021, 379 (2) 108-116; DOI: https://doi.org/10.1124/jpet.121.000655
Michelle R. Doyle
Department of Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas (M.R.D., G.T.C.); South Texas Veterans Health Care System, San Antonio, Texas (M.R.D., G.T.C.); and Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, NIDA and NIAAA, Bethesda, Maryland (A.S., K.C.R.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Agnieszka Sulima
Department of Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas (M.R.D., G.T.C.); South Texas Veterans Health Care System, San Antonio, Texas (M.R.D., G.T.C.); and Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, NIDA and NIAAA, Bethesda, Maryland (A.S., K.C.R.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenner C. Rice
Department of Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas (M.R.D., G.T.C.); South Texas Veterans Health Care System, San Antonio, Texas (M.R.D., G.T.C.); and Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, NIDA and NIAAA, Bethesda, Maryland (A.S., K.C.R.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory T. Collins
Department of Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas (M.R.D., G.T.C.); South Texas Veterans Health Care System, San Antonio, Texas (M.R.D., G.T.C.); and Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, NIDA and NIAAA, Bethesda, Maryland (A.S., K.C.R.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

A subset of rats that self-administer 3,4-methylenedioxypyrovalerone (MDPV) develop unusually high levels of drug taking. A history of responding maintained by cocaine, but not food, prevents the development of this high-responder phenotype; however, it is unclear how histories of noncontingent cocaine exposure or self-administering drugs from other pharmacological classes would affect its development. In the current studies, 5 groups of male Sprague-Dawley rats were used to determine whether histories of responding maintained by drugs from different pharmacological classes (e.g., MDPV, cocaine, fentanyl, nicotine, or ketamine) would differentially impact the development of the high-responder phenotype when MDPV was available for self-administration. Two additional groups were used to determine whether noncontingent exposure to cocaine would prevent the development of the high-responder phenotype when MDPV was available for self-administration, and whether noncontingent exposure to MDPV would facilitate the development of the high-responder phenotype when cocaine was available for self-administration. Consistent with previous reports, a history of response-contingent cocaine, and to a lesser extent noncontingent cocaine, prevented the MDPV high-responder phenotype; however, when responding was initially maintained by fentanyl, nicotine, or ketamine, the MDPV high-responder phenotype developed in ∼45% of rats. By manipulating behavioral and pharmacological histories prior to evaluating MDPV self-administration, the current studies provide additional evidence that a history of response-contingent (or noncontingent) cocaine can prevent the transition from well regulated to aberrant drug-taking when responding is maintained by MDPV. Although the mechanism(s) that underlies this novel high-responder phenotype are unknown, elucidation may provide insight into individual differences relating to substance use disorder.

SIGNIFICANCE STATEMENT A subset of outbred Sprague-Dawley rats self-administer high levels of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). Understanding the behavioral and/or pharmacological factors that can prevent the development of dysregulated MDPV self-administration may provide insight into individual differences in vulnerability to develop a substance use disorder.

Footnotes

    • Received April 8, 2021.
    • Accepted August 16, 2021.
  • This work was supported by the National Institutes of Health National Institute of Drug Abuse [R01 DA039146; R36 DA050955], the jointly sponsored National Institutes of Health Predoctoral Training Program in the Neurosciences [T32 NS082145], and the Intramural Research Programs of the National Institute on Drug Abuse and the National Institute of Alcohol Abuse and Alcoholism.

  • No author has an actual or perceived conflict of interest with the contents of this article.

  • Part of this work was presented as a poster or oral presentation at the following conferences: Doyle MR, DeSantis RE, Sulima A, Rice KC, Collins GT (2019) Influence of drug histories on the development of high levels of MDPV self-administration. College on Problems of Drug Dependence Annual Meeting; San Antonio, TX. Doyle MR, DeSantis RE, Sulima A, Rice KC, Collins GT (2019) Effects of response-contingent and noncontingent drug history on the development of high levels of MDPV self-administration. Experiment Biology/ASPET Annual Meeting; Orlando, FL. Doyle MR, DeSantis RE, Sulima A, Rice KC, Collins GT (2019) Individual differences in high levels of MDPV self-administration: interactions with nicotine. Behavior, Biology and Chemistry: Translational Research in Addiction Annual Meeting; San Antonio, TX.

  • https://dx.doi.org/10.1124/jpet.121.000655.

  • Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 379 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 379, Issue 2
1 Nov 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Influence of Contingent and Noncontingent Drug Histories on the Development of High Levels of MDPV Self-Administration
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleBehavioral Pharmacology

Effects of Drug Histories on MDPV Self-Administration

Michelle R. Doyle, Agnieszka Sulima, Kenner C. Rice and Gregory T. Collins
Journal of Pharmacology and Experimental Therapeutics November 1, 2021, 379 (2) 108-116; DOI: https://doi.org/10.1124/jpet.121.000655

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleBehavioral Pharmacology

Effects of Drug Histories on MDPV Self-Administration

Michelle R. Doyle, Agnieszka Sulima, Kenner C. Rice and Gregory T. Collins
Journal of Pharmacology and Experimental Therapeutics November 1, 2021, 379 (2) 108-116; DOI: https://doi.org/10.1124/jpet.121.000655
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Daily methocinnamox on fentanyl self-administration
  • Efficacy as a determinant of hyperlocomotion by MOR ligands
  • Abuse potential of botanical cannabidiol
Show more Behavioral Pharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics